1. Home
  2. DLPN vs LPTX Comparison

DLPN vs LPTX Comparison

Compare DLPN & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DLPN
  • LPTX
  • Stock Information
  • Founded
  • DLPN 1996
  • LPTX 2011
  • Country
  • DLPN United States
  • LPTX United States
  • Employees
  • DLPN N/A
  • LPTX N/A
  • Industry
  • DLPN Other Consumer Services
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • DLPN Consumer Discretionary
  • LPTX Health Care
  • Exchange
  • DLPN Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • DLPN 12.6M
  • LPTX 11.1M
  • IPO Year
  • DLPN N/A
  • LPTX N/A
  • Fundamental
  • Price
  • DLPN $1.38
  • LPTX $0.32
  • Analyst Decision
  • DLPN Strong Buy
  • LPTX Hold
  • Analyst Count
  • DLPN 1
  • LPTX 1
  • Target Price
  • DLPN $5.00
  • LPTX N/A
  • AVG Volume (30 Days)
  • DLPN 78.9K
  • LPTX 749.3K
  • Earning Date
  • DLPN 11-13-2025
  • LPTX 11-12-2025
  • Dividend Yield
  • DLPN N/A
  • LPTX N/A
  • EPS Growth
  • DLPN N/A
  • LPTX N/A
  • EPS
  • DLPN N/A
  • LPTX N/A
  • Revenue
  • DLPN $51,257,243.00
  • LPTX N/A
  • Revenue This Year
  • DLPN $9.05
  • LPTX N/A
  • Revenue Next Year
  • DLPN $15.42
  • LPTX N/A
  • P/E Ratio
  • DLPN N/A
  • LPTX N/A
  • Revenue Growth
  • DLPN 4.84
  • LPTX N/A
  • 52 Week Low
  • DLPN $0.75
  • LPTX $0.22
  • 52 Week High
  • DLPN $1.78
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • DLPN 67.15
  • LPTX 57.28
  • Support Level
  • DLPN $1.14
  • LPTX $0.28
  • Resistance Level
  • DLPN $1.21
  • LPTX $0.29
  • Average True Range (ATR)
  • DLPN 0.06
  • LPTX 0.02
  • MACD
  • DLPN 0.02
  • LPTX 0.00
  • Stochastic Oscillator
  • DLPN 100.00
  • LPTX 98.75

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Share on Social Networks: